bezafibrate has been researched along with Diabetes Mellitus, Adult-Onset in 77 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (10.39) | 18.7374 |
| 1990's | 18 (23.38) | 18.2507 |
| 2000's | 34 (44.16) | 29.6817 |
| 2010's | 15 (19.48) | 24.3611 |
| 2020's | 2 (2.60) | 2.80 |
| Authors | Studies |
|---|---|
| Henke, BR | 1 |
| Aoki, T; Asaki, T; Hamamoto, T; Kuwabara, K; Murakami, K; Ohmachi, S; Sugiyama, Y; Todo, M | 1 |
| Chen, Y; Mu, T; Shao, Q; Tong, N; Yang, X; Zhang, X; Zhang, Y; Zhou, Y | 1 |
| Akahane, M; Habu, Y; Honda, A; Ishii, I; Kamata, S; Kaneko, C; Machida, Y; Miyawaki, S; Oyama, T; Shiiyama, Y; Uchii, K | 1 |
| Imamura, H; Kawana, H; Nagayama, D; Nakamura, S; Ohira, M; Oka, R; Saiki, A; Sato, Y; Shimizu, N; Shirai, K; Tanaka, S; Tatsuno, I; Watanabe, Y; Yamaguchi, T | 1 |
| Amit, U; Fisman, EZ; Goldenberg, I; Klempfner, R; Matetzky, S; Shemesh, J; Tenenbaum, A | 1 |
| Annema, W; de Boer, JF; Dullaart, RP; Tietge, UJ; Triolo, M | 1 |
| Chambers, ST; Elmslie, JL; George, PM; Krebs, JD; Lever, M; Lunt, H; McEntyre, CJ; Parry-Strong, A; Slow, S | 1 |
| Aso, Y; Fukushima, M; Inukai, T; Momobayashi, A; Omori, K; Terasawa, T | 1 |
| Kaneto, H; Matsuoka, TA; Miyatsuka, T; Shimo, N; Shimomura, I; Takahara, M; Takebe, S; Tochino, Y | 1 |
| Goldbourt, U; Lutski, M; Tanne, D; Weinstein, G | 1 |
| Ellenberg, S; Flory, JH; Hennessy, S; Strom, BL; Szapary, PO | 1 |
| Barbosa Aguila, M; de Souza Mendonca, L; Evangelista Carneiro, R; Fernandes-Santos, C; Mandarim-de-Lacerda, CA | 1 |
| de Vries, R; Dullaart, RP; Sluiter, WJ; van Tol, A; Voorbij, HA | 1 |
| Kotani, K; Satoh, N; Yamada, T | 1 |
| Balasubramanian, R; Cobelli, C; Dalla Man, C; English, PT; Firbank, MJ; Gerrard, J; Lane, A; Taylor, R | 1 |
| Ahnström, J; Dahlbäck, B; de Vries, R; Dikkeschei, BD; Dullaart, RP; Kappelle, PJ; Nielsen, LB; Sluiter, WJ; van Tol, A; Wolffenbuttel, BH | 1 |
| Inazu, A; Ito, N; Kawashiri, MA; Kobayashi, J; Mabuchi, H; Noguchi, T; Nohara, A; Oka, R; Sugihara, M; Tada, H; Takata, M; Yagi, K; Yamaaki, N; Yamagishi, M | 1 |
| Daida, H; Shirai, K; Teramoto, T; Yamada, N | 1 |
| Constantinides, A; de Vries, R; Dullaart, RP; Gautier, T; Lagrost, L; Tselepis, AD; van Leeuwen, JJ; van Pelt, LJ | 1 |
| Fisman, EZ; Tenenbaum, A | 1 |
| Dallinga-Thie, GM; de Vries, R; Dikkeschei, BD; Dullaart, RP; Sluiter, WJ; van Tol, A | 1 |
| Hosoi, T; Ito, H; Kazama, H; Okazaki, M; Orimo, H; Usui, S | 1 |
| Jia, D; Otsuki, M | 1 |
| Narce, M; Poisson, JP | 1 |
| Jia, D; Otani, M; Otsuki, M; Yamamoto, M | 1 |
| Carmody, MW; Davidoff, AJ; Davidson, MB; Hintz, KK; Mason, MM; Podolin, DA; Ren, J; Wold, LE | 1 |
| Adler, Y; Behar, S; Boyko, V; Fisman, EZ; Goldenberg, I; Leor, J; Mandelzweig, L; Motro, M; Schwammenthal, E; Tenenbaum, A | 1 |
| Akahane, S; Matsuzawa, A; Mori, Y; Oana, F; Tajima, N; Tokutate, Y | 1 |
| Akahane, S; Matsuzawa, A; Mori, Y; Oana, F; Tajima, N | 1 |
| Adler, Y; Behar, S; Boyko, V; Fisman, EZ; Leor, J; Motro, M; Schwammenthal, E; Shemesh, J; Tanne, D; Tenenbaum, A | 1 |
| Fisman, EZ; Motro, M; Tenenbaum, A | 1 |
| Fukushima, H; Jinnouchi, H; Koga, H; Kugiyama, K; Ogawa, H; Sakamoto, T; Sugiyama, S; Watanabe, K; Yoshimura, M | 1 |
| Miller, M | 1 |
| Adler, Y; Behar, S; Boyko, V; Feinberg, M; Fisman, EZ; Lapidot, M; Matas, Z; Motro, M; Schwammenthal, E; Tanne, D; Tenenbaum, A; Tenenbaum, H | 1 |
| Vos, E | 1 |
| Kawakami, M; Kawano, M; Senba, H | 1 |
| Aso, Y; Bruemmer, D; Fuentes, L; Gizard, F; Heywood, EB; Inukai, T; Jones, KL; Nakamachi, T; Nomiyama, T; Staels, B; Takebayashi, K; Zhao, Y | 1 |
| Hübinger, A; Müller, HJ; Vogelberg, KH | 1 |
| Alberti, KG; Dyer, RG; Laker, MF; Stewart, MW | 1 |
| Akabane, S; Inoue, I; Ishii, J; Katayama, S; Kawazu, S; Negishi, K; Suzuki, M; Takahashi, K | 1 |
| Cassader, M; Gambino, R; Niort, G; Pagano, G | 1 |
| Behar, S; Boyko, V; Goldbourt, U; Jonas, M; Mandelzweig, L; Reicher-Reiss, H; Shotan, A | 1 |
| Attia, N; Durlach, V; Girard-Globa, A; Labrousse, F; Landron, F; Leutenegger, M; Paul, JL; Roche, D; Soni, T; Zahouani, A | 1 |
| Fujishlma, M; Iwase, M; Takano, K; Waklsaka, M; Yamamoto, M; Yoshinari, M | 1 |
| Jeck, T; Keller, U; Riesen, WF | 1 |
| Lakatos, J; Molnár, M; Tóth, K | 1 |
| Dhanjil, S; Diamond, JR; Elkeles, RS; Feher, MD; Mahmood, S; Mather, H; Nicolaides, AN; Poulter, C; Richmond, W; Sharp, P | 1 |
| Fujiwara, Y; Hasegawa, T; Kawakami, Y; Nakakoshi, T; Nishihara, H; Tagami, S | 1 |
| Adzet, T; Alegret, M; Cabrero, A; Laguna, JC; Llaverías, G; Roglans, N; Sánchez, R; Vázquez, M | 1 |
| Anyaoku, V; Diamond, JR; Elkeles, RS; Hughes, C; Richmond, W | 1 |
| Fukuda, M; Ito, S; Lee, R; Ogawa, S; Sato, T; Sugimura, K; Takeuchi, K | 1 |
| Attia, N; Cambilleau, M; Durlach, V; Girard-Globa, A; Roche, D | 1 |
| Gavish, D; Leibovitz, E; Rubinstein, A; Shapira, I | 1 |
| Bujac, SR; Diamond, JR; Elkeles, RS; Evans, D; Flavell, DM; Humphries, SE; Jamshidi, Y; Miller, G; Pineda Torra, I; Staels, B; Talmud, PJ | 1 |
| Doi, K; Fukushima, M; Nagasaka, S; Nagata, I; Nakai, Y; Sakai, M; Taniguchi, A; Tokuyama, K | 1 |
| Durrington, P | 1 |
| Oboubie, K; Ogunko, A | 1 |
| Attia, N; Autran, D; Dedecjus, M; Durlach, V; Girard-Globa, A | 1 |
| Doi, K; Fukunaga, A; Fukushima, M; Kishimoto, H; Kitatani, N; Matsuura, T; Nagasaka, S; Nagata, I; Nakai, Y; Nakaishi, S; Okumura, T; Sakai, M; Taniguchi, A; Tokuyama, K; Yamashita, Y | 1 |
| Robinson, S; Valabhji, J | 1 |
| Beynen, AC; Donker, AJ; Heine, RJ; Rustemeijer, C; Schouten, JA; Voerman, HJ | 1 |
| Mori, M; Nagai, T; Nakajima, K; Tomizawa, T | 1 |
| Kanazawa, Y; Kawakami, M; Kawano, M; Kuroda, Y; Terao, M; Yaginuma, T | 1 |
| Branchi, A; Fasoli, A; Gandini, R; Maraffi, F; Montalto, C; Rovellini, A; Sommariva, D | 1 |
| Alberti, KG; Jones, IR; Laker, MF; Swai, AB; Taylor, R | 1 |
| Barradas, MA; Dandona, P; Mathur, S; Mikhailidis, DP | 2 |
| Frishman, WH; Kahn, S; Zimetbaum, P | 1 |
| Alberti, KG; Jones, IR; Laker, MF; Miller, M; Swai, A; Taylor, R | 1 |
| Capaldo, B; Genovese, S; Mancini, M; Marotta, G; Patti, L; Postiglione, A; Riccardi, G; Rivellese, A; Saldalamacchia, G | 1 |
| Elkeles, RS; Richmond, W; Seviour, PW; Teal, TK | 1 |
| Benker, G; Cissewski, K; Kienast, K; Reinwein, D; Windeck, R | 1 |
| Sermukslis, B; Smud, R | 1 |
| Kostner, GM; Schernthaner, G | 1 |
| Cabrera, J; Campos, MM; Escobar Jiménez, F; Núñez, J; Orduña, R; Torres, E; Vílchez Joya, R | 1 |
4 review(s) available for bezafibrate and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Hypoglycemic Agents; Models, Molecular; Molecular Structure; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2004 |
Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
Topics: Animals; Bezafibrate; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Insulin Resistance; Lipids; Peroxisome Proliferator-Activated Receptors; Risk Assessment; Risk Factors; Treatment Outcome | 2012 |
Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol, HDL; Coronary Disease; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR delta; PPAR gamma; Triglycerides | 2005 |
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
Topics: Bezafibrate; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type 2; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Kidney Diseases; Lipoproteins, VLDL; Metabolic Clearance Rate; Triglycerides | 1991 |
33 trial(s) available for bezafibrate and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Bezafibrate Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Hypertriglyceridemic Patients with Type 2 Diabetes Mellitus.
Topics: Aged; Ankle; Ankle Brachial Index; Atherosclerosis; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Oxidative Stress; Risk Factors; Triglycerides; Vascular Stiffness | 2019 |
Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes.
Topics: Anti-Inflammatory Agents; Antioxidants; Bezafibrate; Cholesterol; Cholesterol, HDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; High-Density Lipoproteins, Pre-beta; Humans; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Simvastatin | 2014 |
Extreme urinary betaine losses in type 2 diabetes combined with bezafibrate treatment are associated with losses of dimethylglycine and choline but not with increased losses of other osmolytes.
Topics: Adult; Aged; Betaine; Bezafibrate; Choline; Diabetes Mellitus, Type 2; Female; Glycerylphosphorylcholine; Homocysteine; Humans; Hypolipidemic Agents; Inositol; Male; Middle Aged; Sarcosine; Taurine; Young Adult | 2014 |
Insulin Resistance and Future Cognitive Performance and Cognitive Decline in Elderly Patients with Cardiovascular Disease.
Topics: Aged; Bezafibrate; Cardiovascular Diseases; Cognition; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Insulin Resistance; Linear Models; Longitudinal Studies; Male; Middle Aged | 2017 |
Serum paraoxonase-I activity is unaffected by short-term administration of simvastatin, bezafibrate, and their combination in type 2 diabetes mellitus.
Topics: Aged; Anticholesteremic Agents; Aryldialkylphosphatase; Bezafibrate; Carboxylic Ester Hydrolases; Case-Control Studies; Cholesterol, HDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Male; Middle Aged; Simvastatin; Statistics as Topic | 2009 |
Plasma apolipoprotein M responses to statin and fibrate administration in type 2 diabetes mellitus.
Topics: Apolipoproteins; Apolipoproteins M; Bezafibrate; Blood Pressure; Cholesterol; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipocalins; Male; Middle Aged; Placebos; Simvastatin | 2010 |
Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover study
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adipokines; Adiponectin; Adult; Aged; Bezafibrate; Body Mass Index; Cholesterol; Cholesterol, HDL; Cross-Over Studies; Deoxyguanosine; Diabetes Mellitus, Type 2; Female; Fenofibrate; Glucose Tolerance Test; Humans; Leptin; Male; Middle Aged; Peroxisome Proliferator-Activated Receptors; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases; Time Factors; Triglycerides | 2011 |
Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Bezafibrate; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Humans; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Simvastatin; Triglycerides | 2012 |
Statin and fibrate combination does not additionally lower plasma cholesteryl ester transfer in type 2 diabetes mellitus.
Topics: Adult; Bezafibrate; Case-Control Studies; Cholesterol Ester Transfer Proteins; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Placebos; Simvastatin | 2012 |
Effects of bezafibrate and pravastatin on remnant-like lipoprotein particles and lipoprotein subclasses in type 2 diabetes.
Topics: Aged; Aged, 80 and over; Bezafibrate; Cholesterol; Chromatography, High Pressure Liquid; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Triglycerides | 2003 |
Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.
Topics: Aged; Bezafibrate; Blood Glucose; Cholesterol; Comorbidity; Coronary Disease; Diabetes Mellitus, Type 2; Disease Progression; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hypercholesterolemia; Hypolipidemic Agents; Incidence; Insulin; Life Tables; Male; Middle Aged; Myocardial Infarction; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2004 |
Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients.
Topics: Adult; Aged; Bezafibrate; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Humans; Hypolipidemic Agents; Lipids; Male; Middle Aged; Obesity; Prospective Studies; Treatment Outcome | 2005 |
Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes.
Topics: Aged; Bezafibrate; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Female; Follow-Up Studies; Homeostasis; Humans; Hypolipidemic Agents; Inflammation; Insulin Resistance; Insulin-Secreting Cells; Lipids; Male; Middle Aged; Placebos | 2007 |
[The somatostatin infusion test for the evaluation of glucose utilization in bezafibrate medication].
Topics: Adult; Bezafibrate; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Humans; Insulin; Insulin Resistance; Somatostatin; Time Factors | 1984 |
The effects of lipid lowering drugs on metabolic control and lipoprotein composition in type 2 diabetic patients with mild hyperlipidaemia.
Topics: Apolipoproteins B; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Middle Aged; Phospholipids; Placebos; Pyrazines; Simvastatin; Triglycerides | 1995 |
Improvement of glucose tolerance by bezafibrate in non-obese patients with hyperlipidemia and impaired glucose tolerance.
Topics: Bezafibrate; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Follow-Up Studies; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypercholesterolemia; Hyperlipidemias; Insulin; Male; Middle Aged; Pravastatin | 1994 |
Bezafibrate affects lipid, lipo- and apolipoprotein pattern in non-insulin-dependent diabetic patients.
Topics: Apolipoproteins; Bezafibrate; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipoproteinemia Type II; Lipid Metabolism; Lipoproteins; Male; Middle Aged; Single-Blind Method | 1993 |
Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Bezafibrate Infarction Prevention (BIP) Study Group.
Topics: Actuarial Analysis; Adrenergic beta-Antagonists; Aged; Bezafibrate; Case-Control Studies; Coronary Disease; Databases, Factual; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Risk Factors; Time Factors | 1996 |
Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM.
Topics: Aged; Apolipoproteins; Bezafibrate; Creatine Kinase; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fibrinogen; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Patient Compliance; Simvastatin | 1997 |
Efficacy and tolerance of 400 MG bezafibrate in diabetic and hyperlipidaemic patients.
Topics: Adolescent; Adult; Aged; Bezafibrate; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Risk Factors | 1996 |
Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study.
Topics: Adult; Aged; Bezafibrate; Carotid Arteries; Cholesterol; Cholesterol, HDL; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Electrocardiography; Exercise Test; Female; Femoral Artery; Fibrinogen; Follow-Up Studies; Humans; Hypolipidemic Agents; Lipids; Lipoproteins; Male; Middle Aged; Placebos; Time Factors; Triglycerides; Ultrasonography | 1998 |
Long term improvement in dyslipidaemia in Type 2 diabetes with bezafibrate is not related to changes in insulin resistance.
Topics: Bezafibrate; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Lipoproteins, HDL; Lipoproteins, LDL; Reference Values; Treatment Outcome | 1999 |
Bezafibrate reduces blood glucose in type 2 diabetes mellitus.
Topics: Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypolipidemic Agents; Leptin; Male; Middle Aged; Triglycerides; Tumor Necrosis Factor-alpha | 2000 |
Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety.
Topics: Aged; Bezafibrate; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Simvastatin; Time Factors; Treatment Outcome | 2000 |
Effect of bezafibrate on insulin sensitivity in nonobese Japanese type 2 diabetic patients.
Topics: Asian People; Bezafibrate; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypertriglyceridemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Japan; Male; Middle Aged | 2000 |
Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients.
Topics: Adult; Aged; Bezafibrate; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Japan; Male; Middle Aged | 2001 |
Effect of bezafibrate on metabolic profiles in non-insulin-dependent diabetes mellitus.
Topics: Bezafibrate; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Humans; Middle Aged; Triglycerides | 1990 |
Bezafibrate retard in type II diabetic patients: effects on hemostasis and glucose homeostasis.
Topics: Adult; Aged; Bezafibrate; Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Female; Hemostasis; Homeostasis; Humans; Lipids; Male; Middle Aged; Platelet Aggregation | 1990 |
The effect of a slow release formulation of bezafibrate on lipids, glucose homeostasis, platelets and fibrinogen in type II diabetics: a pilot study.
Topics: Adenosine Diphosphate; Bezafibrate; Blood Glucose; Blood Platelets; Cholesterol; Collagen; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Fibrinogen; Homeostasis; Humans; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Triglycerides | 1990 |
Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM.
Topics: Bezafibrate; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Fatty Acids, Nonesterified; Female; Glucose Tolerance Test; Humans; Male; Middle Aged; Triglycerides | 1990 |
Effects of bezafibrate on insulin secretion and peripheral insulin sensitivity in hyperlipidemic patients with and without diabetes.
Topics: Adult; Bezafibrate; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hyperlipoproteinemias; Insulin; Insulin Secretion; Male; Middle Aged; Triglycerides | 1989 |
Serum lipids, lipoproteins and macrovascular disease in non-insulin-dependent diabetics: a possible new approach to prevention.
Topics: Aged; Alkaline Phosphatase; Apoproteins; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Lipoproteins, HDL; Male; Middle Aged; Prospective Studies; Triglycerides | 1988 |
Bezafibrate and fenofibrate in type II diabetics with hyperlipoproteinaemia.
Topics: Adult; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fenofibrate; Humans; Hyperlipoproteinemias; Hypoglycemic Agents; Hypolipidemic Agents; Male; Middle Aged; Propionates; Triglycerides | 1987 |
40 other study(ies) available for bezafibrate and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dioxanes; Disease Models, Animal; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipoproteins; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred Strains; Molecular Structure; Oxazoles; PPAR alpha; Structure-Activity Relationship; Triglycerides | 2008 |
Maternally inherited diabetes and deafness coexists with lipoprotein lipase gene mutation-associated severe hyperlipidemia that was resistant to fenofibrate and atorvastatin, but sensitive to bezafibrate: A case report.
Topics: Atorvastatin; Bezafibrate; Deafness; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hyperlipidemias; Lipoprotein Lipase; Mitochondrial Diseases; Mutation | 2022 |
Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate.
Topics: Benzoxazoles; Bezafibrate; Butyrates; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; Ligands; Non-alcoholic Fatty Liver Disease; PPAR alpha; PPAR delta; PPAR gamma | 2022 |
Comparison of statin alone versus bezafibrate and statin combination in patients with diabetes mellitus and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Bezafibrate; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Israel; Male; Middle Aged; Morbidity; Prospective Studies; Survival Rate; Treatment Outcome | 2014 |
Bezafibrate, a peroxisome proliferator-activated receptor α agonist, decreases circulating CD14(+)CD16(+) monocytes in patients with type 2 diabetes.
Topics: Adult; Bezafibrate; Cross-Sectional Studies; Cytokines; Diabetes Mellitus, Type 2; Female; Gene Expression; Glucose Intolerance; GPI-Linked Proteins; Humans; Inflammation Mediators; Lipopolysaccharide Receptors; Male; Middle Aged; Monocytes; PPAR alpha; Receptors, IgG; RNA, Messenger; Translational Research, Biomedical | 2015 |
Short-term selective alleviation of glucotoxicity and lipotoxicity ameliorates the suppressed expression of key β-cell factors under diabetic conditions.
Topics: Animals; Apoptosis; Benzhydryl Compounds; Bezafibrate; Cell Proliferation; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gene Expression; Glucose; Glucosides; Hypoglycemic Agents; Islets of Langerhans; Lipids; Mice | 2015 |
Antidiabetic action of bezafibrate in a large observational database.
Topics: Aged; Bezafibrate; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Middle Aged; Retrospective Studies | 2009 |
Rosiglitazone aggravates nonalcoholic Fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet.
Topics: Adipose Tissue; Animals; Bezafibrate; Blood Glucose; Diabetes Mellitus, Type 2; Dietary Fats; Dietary Sucrose; Energy Metabolism; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Mice; Mice, Inbred C57BL; Obesity; Pancreatic Diseases; PPAR alpha; PPAR-beta; Rosiglitazone; Thiazolidinediones; Weight Gain | 2009 |
Bezafibrate and serum amyloid A--low-density lipoprotein complex in patients with type 2 diabetes mellitus and hypertriglyceridemia.
Topics: Bezafibrate; Diabetes Mellitus, Type 2; Female; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Serum Amyloid A Protein; Triglycerides | 2010 |
Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.
Topics: Abdominal Muscles; Adult; Aged; Bezafibrate; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Insulin Resistance; Liver; Middle Aged; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Triglycerides | 2010 |
Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study.
Topics: Aged; Bezafibrate; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Glucose; Glycated Hemoglobin; Humans; Hypolipidemic Agents; Japan; Lipid Metabolism; Male; Middle Aged; Prospective Studies; Retrospective Studies; Treatment Outcome; Triglycerides | 2012 |
Bezafibrate, a peroxisome proliferator-activated receptor (PPAR)-alpha activator, prevents pancreatic degeneration in obese and diabetic rats.
Topics: Actins; Animals; Bezafibrate; Blood Glucose; Cytokines; Diabetes Mellitus, Type 2; Hypolipidemic Agents; Insulin; Lipids; Obesity; Organ Size; Pancreas; Rats; Rats, Inbred OLETF; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2003 |
Novel PPARgamma-dependent and independent effects for thiazolidinediones.
Topics: Animals; Bezafibrate; Body Weight; Chromans; Diabetes Mellitus, Type 2; Gene Expression; Humans; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Growth Factor Binding Proteins; Mice; Monocytes; Pancreas; Pioglitazone; PPAR alpha; PPAR gamma; Pregnancy Proteins; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Troglitazone; Tumor Necrosis Factor-alpha | 2003 |
Bezafibrate on lipids and glucose metabolism in obese diabetic Otsuka Long-Evans Tokushima fatty rats.
Topics: Adipose Tissue; Animals; Bezafibrate; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Eating; Fatty Acids, Nonesterified; Glucose; Glucose Tolerance Test; Hypolipidemic Agents; Immunohistochemistry; Insulin; Insulin Resistance; Islets of Langerhans; Lipid Metabolism; Lipids; Obesity; Pancreas; Rats; Rats, Inbred OLETF; Triglycerides | 2004 |
Sucrose-induced cardiomyocyte dysfunction is both preventable and reversible with clinically relevant treatments.
Topics: Animals; Bezafibrate; Diabetes Mellitus, Type 2; Dietary Sucrose; Heart Diseases; Hyperinsulinism; Hypolipidemic Agents; Insulin Resistance; Male; Myocardial Contraction; Myocytes, Cardiac; Physical Conditioning, Animal; Physical Exertion; Rats; Rats, Wistar | 2004 |
Bezafibrate-induced changes over time in the expression of uncoupling protein (UCP) mRNA in the tissues: a study in spontaneously type 2 diabetic rats with visceral obesity.
Topics: Animals; Bezafibrate; Blood Glucose; Body Weight; Carrier Proteins; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Eating; Fatty Acids; Gene Expression Regulation; Hypolipidemic Agents; Insulin; Ion Channels; Leptin; Male; Membrane Proteins; Membrane Transport Proteins; Mitochondrial Proteins; Obesity; PPAR alpha; PPAR delta; Rats; Rats, Inbred Strains; RNA, Messenger; Thyroid Hormones; Uncoupling Agents; Uncoupling Protein 1; Uncoupling Protein 2; Uncoupling Protein 3; Viscera | 2004 |
Short-term effect of bezafibrate on the expression of adiponectin mRNA in the adipose tissues: a study in spontaneously type 2 diabetic rats with visceral obesity.
Topics: Adiponectin; Adipose Tissue; Animals; Bezafibrate; Blood Glucose; Cholesterol, VLDL; Chylomicrons; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Hypolipidemic Agents; Intercellular Signaling Peptides and Proteins; Male; Obesity; Rats; Rats, Inbred OLETF; RNA, Messenger | 2004 |
Elevated levels of remnant lipoproteins are associated with plasma platelet microparticles in patients with type-2 diabetes mellitus without obstructive coronary artery disease.
Topics: Angina Pectoris; Bezafibrate; Blood Platelets; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Risk Factors | 2006 |
Bezafibrate reduces the incidence of type 2 diabetes mellitus in patients with obesity.
Topics: Aged; Bezafibrate; Body Mass Index; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hypolipidemic Agents; Incidence; Middle Aged; Myocardial Infarction; Obesity; Time Factors; Triglycerides | 2006 |
Multitherapy for diabetes.
Topics: Bezafibrate; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Humans; Hypolipidemic Agents; Pravastatin | 2006 |
Severe decrease in serum HDL-cholesterol during combination therapy of bezafibrate and pioglitazone.
Topics: Bezafibrate; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Male; Middle Aged; Pioglitazone; Thiazolidinediones | 2006 |
PPARalpha agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes.
Topics: Animals; Bezafibrate; Cell Line; Diabetes Mellitus, Type 2; Gene Expression Regulation; Humans; Hypolipidemic Agents; Ligands; Macrophages; Mice; Monocytes; Osteopontin; Plasmids; Polymerase Chain Reaction; PPAR alpha; Pyrimidines; Transfection | 2007 |
Post-prandial metabolism of triglyceride-rich lipoproteins in non-insulin-dependent diabetic patients before and after bezafibrate treatment.
Topics: Aged; Apolipoprotein C-III; Apolipoproteins C; Bezafibrate; Blood Glucose; Chylomicrons; Diabetes Mellitus, Type 2; Dietary Fats; Diterpenes; Fatty Acids, Nonesterified; Humans; Lipoproteins; Male; Middle Aged; Postprandial Period; Retinyl Esters; Triglycerides; Vitamin A | 1997 |
Effect of bezafibrate on hypercoagulability assessed by fluorogenic prothrombin time in hyperlipidemic patients with non-insulin-dependent diabetes mellitus.
Topics: Aged; Bezafibrate; Blood Coagulation; Body Mass Index; Case-Control Studies; Cholesterol; Diabetes Mellitus, Type 2; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Prothrombin Time | 1997 |
Elevation of plasma lipid peroxides in non-insulin dependent diabetics with multiple lacunar infarcts.
Topics: Aged; Bezafibrate; Case-Control Studies; Cerebral Infarction; Diabetes Mellitus, Type 2; Female; Humans; Hypolipidemic Agents; Magnetic Resonance Imaging; Male; Middle Aged; Oxidative Stress; Thiobarbituric Acid Reactive Substances | 1997 |
Uncoupling protein-3 mRNA levels are increased in white adipose tissue and skeletal muscle of bezafibrate-treated rats.
Topics: Adipose Tissue; Animals; Base Sequence; Bezafibrate; Body Weight; Carrier Proteins; Diabetes Mellitus, Type 2; DNA Primers; Hypolipidemic Agents; Insulin Resistance; Ion Channels; Leptin; Male; Mitochondria; Mitochondrial Proteins; Muscle, Skeletal; Organ Size; Proteins; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Uncoupling Protein 3 | 1999 |
Postprandial concentrations and distribution of apo C-III in type 2 diabetic patients. Effect Of bezafibrate treatment.
Topics: Aged; Analysis of Variance; Apolipoprotein C-III; Apolipoproteins C; Apolipoproteins E; Bezafibrate; Diabetes Mellitus, Type 2; Female; Humans; Hypolipidemic Agents; Male; Middle Aged; Postprandial Period; Probability | 2000 |
Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects.
Topics: Apolipoprotein A-I; Bezafibrate; Binding Sites; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; DNA; Fatty Acids, Nonesterified; Female; Humans; Introns; Lipids; Male; Middle Aged; Mutation, Missense; Polymorphism, Single-Stranded Conformational; Prospective Studies; Receptors, Cytoplasmic and Nuclear; Transcription Factors; Transfection | 2000 |
A case for lipid-lowering?
Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Risk Factors; Triglycerides | 2000 |
Therapy and clinical trials.
Topics: Bezafibrate; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Gemfibrozil; Humans; Hypolipidemic Agents | 2000 |
Postprandial reverse cholesterol transport in type 2 diabetic patients: effect of a lipid lowering treatment.
Topics: Bezafibrate; Biological Transport; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypolipidemic Agents; Male; Middle Aged; Postprandial Period | 2000 |
Diabetes and lipids - a conundrum.
Topics: Bezafibrate; Cholesterol, HDL; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Electrocardiography; Humans; Hypolipidemic Agents; Randomized Controlled Trials as Topic; Triglycerides | 2001 |
Is pseudocholinesterase activity related to markers of triacylglycerol synthesis in Type II diabetes mellitus?
Topics: Aged; Anticholesteremic Agents; Apolipoproteins E; Bezafibrate; Biomarkers; Butyrylcholinesterase; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin; Linear Models; Male; Phenotype; Pravastatin; Triglycerides | 2001 |
Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients.
Topics: Albuminuria; Apolipoprotein A-I; Apolipoprotein B-100; Apolipoproteins B; Bezafibrate; Blood Pressure; Case-Control Studies; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Humans; Hypercholesterolemia; Hypolipidemic Agents; Insulin; Lipids; Male; Middle Aged; Pravastatin | 2000 |
Marked removal of bezafibrate-induced high-density lipoprotein-cholesterol by low-density lipoprotein apheresis.
Topics: Aged; Apolipoproteins E; Arteriosclerosis Obliterans; Bezafibrate; Blood Component Removal; Cholesterol, HDL; Diabetes Mellitus, Type 2; Electrophoresis, Agar Gel; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Lipoproteins, LDL; Male | 2002 |
Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type 2 diabetic patients with hyperlipidaemia.
Topics: Aged; Bezafibrate; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Female; Fructosamine; Hemoglobins; Hexosamines; Humans; Hyperlipidemias; Lipids; Lipoproteins, HDL; Male; Middle Aged; Triglycerides | 1992 |
[Diabetes and hyperlipidemia. Increased coronary risk can be prevented].
Topics: Bezafibrate; Coronary Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias | 1988 |
[Bezafibrate-induced myoglobinuric kidney failure in a 54-year-old patient with diabetes mellitus type IIa].
Topics: Acute Kidney Injury; Bezafibrate; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Female; Humans; Middle Aged; Myoglobinuria; Rhabdomyolysis | 1988 |
Apolipoproteins in diabetes mellitus.
Topics: Adult; Apolipoproteins; Bezafibrate; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Insulin; Lipoproteins; Male | 1985 |
[Effects of bezafibrate in patients with combined hyperlipidemia].
Topics: Arteriosclerosis; Bezafibrate; Cholesterol; Diabetes Mellitus, Type 2; Humans; Hyperlipidemia, Familial Combined; Male; Triglycerides | 1986 |